Second, the follow-up duration was limited to two years, which may not fully capture the long-term prognostic implications of IFN-γ and TNF-α, particularly in the context of chronic, progressive diseases such as PAD, CAD, and CVD. The gene discussed is TNF; the disease is peripheral arterial disease.